{"classes":[{"categories":[{"measurements":[{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of participants with an event","groupId":"OG000","lowerLimit":"12.4","upperLimit":"NA","value":"24.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"OS was defined as the time from the first dose of study treatment until death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants received pembrolizumab (MK-3475) 200 mg or pediatric participants received 2 mg/kg (up to 200 mg) on Day 1 Q3W IV for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to ~58 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}